메뉴 건너뛰기




Volumn 5, Issue 12, 2005, Pages 3019-

Is administration of rituximab at 375 mg/m2 without splenectomy appropriate for ABO-incompatible renal transplant? [1]

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

EID: 33644816294     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.01088.x     Document Type: Letter
Times cited : (16)

References (5)
  • 1
    • 3042746307 scopus 로고    scopus 로고
    • Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy
    • Sonnenday CJ Warren DS Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004 4 : 1315 1322.
    • (2004) Am J Transplant , vol.4 , pp. 1315-1322
    • Sonnenday, C.J.1    Warren, D.S.2    Cooper, M.3
  • 2
    • 10744232375 scopus 로고    scopus 로고
    • Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics
    • Vieira CA Agarwal A Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004 77 : 542 548.
    • (2004) Transplantation , vol.77 , pp. 542-548
    • Vieira, C.A.1    Agarwal, A.2    Book, B.K.3
  • 3
    • 0037930774 scopus 로고    scopus 로고
    • Delayed-onset neutropenia associated with rituximab therapy
    • Chaiwatanatorn K Lee N Grigg A et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003 121 : 913 918.
    • (2003) Br J Haematol , vol.121 , pp. 913-918
    • Chaiwatanatorn, K.1    Lee, N.2    Grigg, A.3
  • 4
    • 0037297117 scopus 로고    scopus 로고
    • The mechanisms of action of rituximab in the elimination of tumor cells
    • Johnson P Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003 30 ( Suppl 2 3 8.
    • (2003) Semin Oncol , vol.30 , Issue.2 , pp. 3-8
    • Johnson, P.1    Glennie, M.2
  • 5
    • 21244502171 scopus 로고    scopus 로고
    • Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil
    • Mannami M Mitsuhata N. Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil. Transplantation 2005 79 : 1756 1758.
    • (2005) Transplantation , vol.79 , pp. 1756-1758
    • Mannami, M.1    Mitsuhata, N.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.